Savant Capital LLC Sells 9,281 Shares of Exact Sciences Corporation $EXAS

Savant Capital LLC trimmed its holdings in Exact Sciences Corporation (NASDAQ:EXAS) by 58.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,638 shares of the medical research company’s stock after selling 9,281 shares during the period. Savant Capital LLC’s holdings in Exact Sciences were worth $363,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of EXAS. Integrated Wealth Concepts LLC bought a new position in Exact Sciences during the first quarter valued at approximately $604,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Exact Sciences by 11.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,186 shares of the medical research company’s stock valued at $921,000 after buying an additional 2,231 shares during the period. Great Lakes Advisors LLC boosted its holdings in Exact Sciences by 3.7% during the 1st quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company’s stock valued at $215,000 after acquiring an additional 178 shares during the period. Focus Partners Wealth boosted its stake in shares of Exact Sciences by 12.6% during the first quarter. Focus Partners Wealth now owns 21,548 shares of the medical research company’s stock valued at $933,000 after purchasing an additional 2,413 shares during the period. Finally, Vanguard Personalized Indexing Management LLC grew its stake in Exact Sciences by 22.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 15,796 shares of the medical research company’s stock worth $839,000 after acquiring an additional 2,853 shares in the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on EXAS. Stifel Nicolaus reissued a “hold” rating and set a $105.00 price target (up previously from $80.00) on shares of Exact Sciences in a research report on Friday, November 28th. TD Cowen lowered shares of Exact Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, November 25th. Jefferies Financial Group lowered Exact Sciences from a “buy” rating to a “hold” rating and upped their target price for the company from $90.00 to $105.00 in a research report on Monday, November 24th. Robert W. Baird set a $105.00 price objective on shares of Exact Sciences in a research report on Thursday, November 20th. Finally, Canaccord Genuity Group cut Exact Sciences from a “buy” rating to a “hold” rating and lifted their price target for the stock from $85.00 to $105.00 in a research report on Tuesday, November 25th. Two analysts have rated the stock with a Buy rating, twenty-one have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $89.56.

Insider Transactions at Exact Sciences

In other Exact Sciences news, EVP Jacob A. Orville sold 5,000 shares of the company’s stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price of $75.00, for a total value of $375,000.00. Following the completion of the transaction, the executive vice president owned 23,237 shares in the company, valued at approximately $1,742,775. This represents a 17.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.20% of the company’s stock.

Exact Sciences Stock Up 0.0%

Shares of EXAS stock opened at $103.24 on Friday. Exact Sciences Corporation has a twelve month low of $38.81 and a twelve month high of $103.54. The stock has a market cap of $19.70 billion, a P/E ratio of -93.85, a P/E/G ratio of 2.44 and a beta of 1.42. The stock has a 50 day moving average of $102.10 and a 200 day moving average of $75.76. The company has a current ratio of 2.72, a quick ratio of 2.44 and a debt-to-equity ratio of 0.93.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Friday, February 13th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of $0.08 by ($0.29). The company had revenue of $878.38 million during the quarter, compared to analysts’ expectations of $860.59 million. Exact Sciences had a positive return on equity of 1.67% and a negative net margin of 32.01%.The company’s revenue for the quarter was up 23.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.06) EPS. As a group, sell-side analysts expect that Exact Sciences Corporation will post -0.58 EPS for the current year.

Exact Sciences Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.